Health Economics and Outcomes Research

Healthcare Economist

The Need for Continuous Cost-Effectiveness Analysis

07/06/2020

Jason Shafrin, PhD, highlights a study noting that value assessment is not a one-time endeavor but needs to be revisited as a treatment landscape evolves.

Jason Shafrin, PhD, highlights a...

07/06/2020

Journal of Clinical Pathways

News

Financial Hardship Associated With Increased ED Visits, Less Preventive Care

06/23/2020

A study from the American Cancer Society found higher medical and non-medical financial hardships are independently associated with more ED visits, lower receipt of some preventive services, and worse self-reported...

A...

06/23/2020

Journal of Clinical Pathways

News

First Ever Oncology Hospital-At-Home Evaluation Shows Better Outcomes, Lower Costs

06/02/2020

The first ever reported trial of an adult oncology hospital-at-home program shows strong evidence for reduced hospitalizations, ED visits, and costs, according to a presentation at the American Society of Clinical...

The...

06/02/2020

Journal of Clinical Pathways

News

Provider Perceptions of Cost, Safety of Oral Oncolytic Agents

05/28/2020

A recent survey shed light on the perceptions of health care workers regarding the cost and safety of oral oncolytic agents, as well as highlighted perceptions of impact on patient care. Results of the survey were...

A...

05/28/2020

Journal of Clinical Pathways

News

Cost-Benefit Analysis Shows Difference in Price, Clinical Benefit of Cancer Drugs in US, Europe

05/26/2020

A cost-benefit analysis published in The Lancet Oncology (May 2020;21[5]:664-670) compared the prices and clinical benefit of cancer drugs in the US vs Europe. Both the US and European countries are faced with the...

A...

05/26/2020

Journal of Clinical Pathways

Research Reports

The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis

05/19/2020

Abdalla Aly , PhD;

Yunes Doleh , MPH, PharmD;

Marc Botteman , MSc;

Courtney Johnson , MPH;

Viktor Chirikov , MS, PhD;

Arif Hussain , MD;

Rahul Shenolikar , MS, PhD;

Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...

...

05/19/2020

Journal of Clinical Pathways

Research in Review

Blood Flow Measurement Predicts Effectiveness of Ovarian Cancer Treatment

07/03/2017

JCP Editors

A tool for measuring blood flow and volume to ovarian cancer tumors accurately predicts the effectiveness of treatment, according to a recent study published in Clinical Cancer Research (June 2017;...

A tool...

07/03/2017

Journal of Clinical Pathways

Research in Review

Targeted Therapy Improves Survival in Older Patients With B-Cell Malignancy

06/27/2017

JCP Editors

A targeting agent is more effective in improving progression-free survival (PFS) and overall survival (OS) than conventional therapy in older patients with a treatment-naïve B-cell malignancy, according to research...

A...

06/27/2017

Journal of Clinical Pathways

Viewpoint

The Current Cost of Cancer Drugs: Physician, Payer and Government Concerns Grow

10/27/2015

Gary Owens , MD;

The August 2015 edition of the Mayo Clinic Proceedings featured an article entitled, “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs”.1 In that article, the authors...

The...

10/27/2015

Journal of Clinical Pathways